AGP Picks
View all

New Jersey Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.

Press releases published on September 17, 2026

Paramus Dental Arts Addresses Rise in Failing Dental Implants Among Longtime North Jersey Patients
Solstice Health Communications Has a GSA Schedule and Can Subcontract for Primes
Solstice Health Communications Has a New GSA Schedule and Can Subcontract for Primes
 Brand Force 5 Wins Two First-Place Honors at 58th NJ Ad Club Jersey Awards
BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies
MediDepot Highlights First Aid and Emergency Preparedness Supplies for Healthcare and Workplace Use
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)
NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vireo Growth Inc. Announces Issuance of Shares in Connection with Altmore Settlement
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MAPS Attends Historic FDA Hearing on Psychedelics
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
GOA Therapeutics Emerges from Stealth with $15.5 Million in Funding and Unveils GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning
AVAVA Announces $45 Million Financing Led by Catalio Capital Management to Accelerate Next Phase of Growth

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Jersey Health Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.